Modulus Therapeutics
Modulus Therapeutics is a pioneering company focused on developing optimized cell therapies for autoimmune diseases. By leveraging the safety profile of Natural Killer (NK) cells and innovative engineering techniques, they aim to create off-the-shelf CAR-NK therapies that enhance patient access and safety. Their approach addresses significant limitations of existing CAR-T therapies, such as patient selection dilemmas and accessibility issues, by eliminating the need for lymphodepletion and offering tailored potency through advanced receptor designs. With a commitment to rapid prototyping and generative design, Modulus is positioned to lead in the cell therapy market, providing effective solutions for underserved autoimmune patients.
Modulus Therapeutics
Modulus Therapeutics is a pioneering company focused on developing optimized cell therapies for autoimmune diseases. By leveraging the safety profile of Natural Killer (NK) cells and innovative engineering techniques, they aim to create off-the-shelf CAR-NK therapies that enhance patient access and safety. Their approach addresses significant limitations of existing CAR-T therapies, such as patient selection dilemmas and accessibility issues, by eliminating the need for lymphodepletion and offering tailored potency through advanced receptor designs. With a commitment to rapid prototyping and generative design, Modulus is positioned to lead in the cell therapy market, providing effective solutions for underserved autoimmune patients.
TL;DR
Founded: 2020
Headquarters: Seattle, Washington, United States
Focus: AI-powered design of off-the-shelf CAR-NK and engineered immune cell therapies for autoimmune diseases
Platform: Convergent Design™ (gene editing, machine learning, multi-omics, high-throughput screening)
Known seed funding: $3.5M (July 2021) led by Madrona
Company Overview
Problem Domain
Autoimmune diseases; limitations in accessibility and safety of existing cell therapies
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
$3,500,000
Round included participation from KdT Ventures and the Allen Institute for AI (AI2); described as oversubscribed.
Investor Signal
“Led by Madrona Venture Group with participation from KdT Ventures and the Allen Institute for AI (AI2)”